Swedbank AB Decreases Stock Holdings in Cencora, Inc. $COR

Swedbank AB lowered its stake in Cencora, Inc. (NYSE:COR) by 51.9% during the fourth quarter, Holdings Channel.com reports. The fund owned 672,545 shares of the company’s stock after selling 726,578 shares during the quarter. Swedbank AB’s holdings in Cencora were worth $227,152,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. United Bank increased its stake in Cencora by 4.5% during the 2nd quarter. United Bank now owns 7,032 shares of the company’s stock worth $2,109,000 after buying an additional 305 shares in the last quarter. Nebula Research & Development LLC purchased a new stake in shares of Cencora in the second quarter valued at about $595,000. Treasurer of the State of North Carolina boosted its holdings in Cencora by 7.9% in the 2nd quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock valued at $25,647,000 after purchasing an additional 6,244 shares during the last quarter. Diversify Advisory Services LLC grew its stake in shares of Cencora by 94.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock valued at $747,000 after buying an additional 1,253 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in shares of Cencora by 26.0% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock valued at $22,025,000 after buying an additional 15,154 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Morgan Stanley set a $380.00 price target on shares of Cencora in a research report on Tuesday, March 17th. Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. JPMorgan Chase & Co. increased their price target on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Wells Fargo & Company raised their price objective on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Finally, Leerink Partners restated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $398.17.

Cencora Trading Up 0.7%

Shares of NYSE COR opened at $305.89 on Wednesday. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The stock has a market capitalization of $59.50 billion, a PE ratio of 36.77, a PEG ratio of 1.42 and a beta of 0.64. Cencora, Inc. has a twelve month low of $271.00 and a twelve month high of $377.54. The stock has a fifty day simple moving average of $332.27 and a 200-day simple moving average of $343.21.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.80 by ($0.05). The firm had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, equities analysts forecast that Cencora, Inc. will post 17.58 earnings per share for the current year.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.